One such inhibitor of RIG-I, enhancer of zeste homolog 2 (EZH2), has been shown to play an epigenetic role in SLE and was proposed as a therapeutic target by Tsou et al. [60]. The gene discussed is RIGI; the disease is systemic lupus erythematosus.